Eastman 3rd Quarter 2026 Sales and Earnings Results Conference Call - EASTMAN CHEMICAL CO

Explicit Guidance:

• Advanced Materials Volume: Full-year 2026 volume mix growth of ~3%; implied Q4 high-single-digit growth required to offset Q3 softness.
• Circular Economy Revenue: 2026 circular sales target of ~$100 million; 2027 target is at least $100 million (with significant momentum expected in packaging/rPET), though specific 2027 numbers deferred pending January economic clarity.
• Operating Cash Flow: Full-year 2026 estimate reduced to $850 million (from $900 million); 2027 outlook expects significant cash flow improvement above $850 million driven by working capital release and normalization.
• Capital Expenditures: 2026 capex expected at ~$400 million; 2027 baseline guidance ~$500 million (including methanolysis expansion and metathesis project), subject to cash flow discipline.
• Earnings/EBITDA: Acetate 2027 earnings expected to remain stable relative to 2026 despite mid-single-digit price declines, driven by volume recovery and utilization tailwinds; Chemical Intermediates (CI) 2027 earnings expected to be "somewhat moderately" below 2026 but not a significant headwind.
• Acetate Volume: Expecting volume improvement in 2027 driven by destocking completion and regained market share.
• Consumer Durables: Projecting mid-single-digit volume growth in 2027 within a down market.
• Automotive: Expects year-over-year contribution from the automotive sector in Q4 2026 and full year, despite sales down 3–4% in 2026.

Business-Segment Outlook:

• Circular Economy (Methanolysis & Triton): Full utilization of the Q3-convered Triton line expected in 2027; capacity expansion to support higher rPET volume for major brands (e.g., Pepsi); incremental earnings from $100M sales estimated at ~$20M in 2026.
• Advanced Materials (AM): Volume growth driven by Triton ("renew value proposition"), innovation in HUD/EV interlayers, and expansion into mid-tier China markets; pricing pressure from raw material spikes (PX) expected to be mitigated by Jan 1 price increases.
• Acetate & Film Products (AFP): Price degradation expected in 2027 (mid-single-digit decline) due to contract renewals, offset by volume growth and asset utilization tailwinds; functional materials business targeting record earnings in 2026 with stable/modest growth expectations for 2027.
• Chemical Intermediates (CI): Q4 2026 earnings expected to be negatively impacted by an unusual $15M headwind (propane/propylene spread arbitrage); Q4 not a reliable proxy for 2027 due to seasonality and temporary market dislocation.
• China Operations: Performance films and interlayers facing headwinds from a ~20% market sales decline in China; strategy shifted to mid-tier market penetration via low-cost asset optimization.

Market and Competitive Outlook:

• Pricing Environment: Full-year 2026 price-cost headwind estimated at ~$30 million (half in Q4); Jan 1 price increases intended to cover raw material challenges moving into 2027.
• Competitive Landscape: No material capacity expansions anticipated from Japanese competitors in interlayer markets due to weak demand; Eastman expects to regain market share lost in 2024–2025 via disciplined pricing and contract roll-outs.
• Industry Dynamics: Acetate market stabilization expected in 2027 due to competitor (Genon/Sirdia) consolidation reducing incentives for new capacity; propylene/arbitrage spread (U.S. vs. Asia) expected to close quickly, potentially adding $30–40M earnings to 2027 vs. Q4.
• Inventory Levels: Days inventory reduced from 115 (end 2025) to 105 (end Q3 2026); inventory tailwind expected in 2027 as working capital normalizes, primarily in Advanced Materials and Fibers.

Macro / Industry Outlook:

• Stagflation: Operating in a "stagflationary" environment (2022–2026) with no significant improvement in end markets (Auto, Housing, Consumer Durables); consumer resilience attributed to employment stability despite affordability pressures.
• Geopolitics & Conflict: Iran conflict driving raw material spikes (PX, oil) and supply chain uncertainty; potential upside in 2027 if conflict resolves, boosting consumer sentiment and demand.
• Economic Conditions: 2027 outlook depends on clarity regarding the Iran war and economic stability; management remains conservative on 2027 guidance until January.
• Exchange Rates & Commodities: Full-year 2026 Brent crude average implies lower pricing for Q4, though Q4 average remains higher than the full-year average; crude price volatility expected to impact 2026 margins but normalize in 2027.

Strategic Initiatives:

• DOE Grant: Department of Energy grant reinstated for Kingsport methanolysis expansion; DOE to cover 30–50% of capital costs for Phase 1 (de-bottlenecking + 2nd plant), significantly lowering Eastman's capex burden.
• Metathesis (E2P) Project: Repurposing existing cracker to metathesis unit; targeting ~$100M average annual earnings with 1–2 year payback; expected online mid-2028; initial investment delayed due to capital discipline and focus on Circular projects.
• Acquisition Strategy: Evaluation of potential capacity synergies following Genon/Sirdia combination; focusing on cost reduction and debt servicing for the combined entity.
• Asset Optimization: Leveraging acquired/low-cost recycling assets (polymer lines, feedstock processing) to reduce capital intensity for the second methanolysis plant compared to the original Longview project.
• Technology Leadership: Demonstrating leadership in U.S. supply chain re-industrialization; expanding regional economy through collection, recycling, and manufacturing jobs.

Risks and Headwinds to Outlook:

• Geopolitical Escalation: Potential re-escalation of Iran conflict could reverse 2027 working capital release and cash flow tailwinds; ongoing supply chain disruptions (propylene shipping) may delay arbitrage normalization.
• Raw Material Volatility: Continued high PX and oil prices could drive larger-than-expected Q4 and 2027 price-cost headwinds if price increases fail to fully offset costs.
• Economic Uncertainty: Slowdown in U.S. construction (-20%), auto sales (-3–4%), and China markets could pressure volume growth; destocking in independent acetate customers could persist.
• Operational Execution: Startup delays on Triton and polymer line conversion in Q3 2026 highlight potential ramp-up risks; 2027 cash flow relies on successful inventory reduction and turnaround timing.
• Market Share Loss: Acetate market share losses (2024–2025) require aggressive pricing/strategies to recover; price degradation expected in 2027 despite volume gains.

Management Tone on the Future:

• Confidence: High confidence in 2027 earnings stability and cash flow improvement ("significant cash flow above $850M") provided macro conditions normalize.
• Cautious Optimism: Conservative on specific 2027 numerical guidance pending January clarity on the economy and war; confident in "mid-single-digit growth" capabilities despite a down market.
• Strategic Focus: Emphasis on capital efficiency, volatility reduction via the metathesis project, and "disciplined" capital allocation to support organic growth and shareholder value.
• Innovation Belief: Strong belief that innovation (e.g., EV interlayers, Triton) will drive growth even in challenged discretionary markets.

Miscellaneous:

• Q3 Operational Issues: $15M Q3 headwind attributed to Triton line pump failures and polymer line startup delays; issues resolved, lines running well with no impact expected in Q4.
• Inventory Strategy: Raw material inventory increases (security of supply) and finished goods production in Q2/Q3 contributed to working capital pressure; release expected in Q4 and 2027.
• Divestment Impact: $50M revenue loss in 2026 relative to 2025 due to exiting low-value medical business, masking underlying organic growth.